NASDAQ
3.77USD
-0.30 (-7.37%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
32.8M
P/E
—
EPS
—
Beta
1.52
52W range
2.6-14.68
Day range
3.46–4.04
Open
4.04
Prev close
4.07
Volume
8.1M
Avg volume
184.2K
Dividend
0.00
IPO
2012-03-14
https://www.globenewswire.com/news-release/2026/08/24/3349644/0/en/briacell-advances-personalized-melanoma-immunotherapy-vaccine-candidate-bria-mel.html · 8/24/2026+0.80
https://www.globenewswire.com/news-release/2026/05/31/3303968/0/en/briacell-therapeutics-announces-pricing-of-offering.html · 5/31/2026+0.20
https://www.globenewswire.com/news-release/2026/02/18/3240709/0/en/BriaCell-and-BriaPro-Enter-Into-Asset-Purchase-Agreement-for-Exclusive-Soluble-CD80-License.html · 2/18/2026+0.40
https://www.barrons.com/articles/american-bitcoin-stock-price-eric-trump-426a9d3b · 12/10/2025+0.80
https://www.globenewswire.com/news-release/2025/10/21/3170083/0/en/BriaCell-Announces-Collaboration-with-MSK-Accelerator-to-Advance-Bria-OTS-for-Breast-Cancer.html · 10/21/2025
https://www.globenewswire.com/news-release/2025/10/13/3165447/0/en/BriaCell-to-Present-Positive-Clinical-Biomarker-Data-of-Phase-3-Study-at-ESMO-2025.html · 10/13/2025+0.80
https://www.zacks.com/stock/news/2750984/all-you-need-to-know-about-briacell-therap-bctx-rating-upgrade-to-buy?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2750984 · 9/12/2025+1.00
https://www.globenewswire.com/news-release/2025/08/25/3138370/0/en/BriaCell-Awarded-2-Million-NCI-Grant-to-Advance-Bria-PROS-in-Prostate-Cancer.html · 8/25/2025+0.80
BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company primarily focused on developing innovative immunotherapies to combat cancer. The firm's leading experimental drug, Bria-IMT, is currently undergoing Phase I/IIa clinical investigation. This crucial study evaluates its effectiveness when utilized in conjunction with immune checkpoint inhibitors for treating breast cancer. Beyond its flagship program, BriaCell has forged a collaborative research and development partnership with the National Cancer Institute (NCI). This alliance is dedicated to progressing Bria-OTS, a personalized immunotherapy designed for advanced breast cancer patients, and BriaDx, a proprietary diagnostic assay. The company's main offices are situated in West Vancouver, Canada.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
